Top ophthalmic business news

The competitive landscape for ophthalmic and optometry business revenue has been apparent in recent weeks as industries have announced their Q2 earnings, acquisitions, pending agreements and other breaking news. Here are the Ocular Surgery News editors' top five ophthalmic business news items published at Healio.com:

1. Alcon to acquire WaveTec Vision, full rights to ORA System

Alcon announced it has entered into an agreement to acquire WaveTec Vision, according to a company press release.

Upon completion of the acquisition, Alcon will gain full rights to the ORA System and plans to immediately begin integration of WaveTec into its surgical business franchise, according to the release. Read more.

2. Beaver-Visitec announces acquisition of Endo Optiks

Beaver-Visitec International has acquired Endo Optiks, maker of a novel endoscopy system, according to a company press release.

“For over 80 years, BVI has been known to offer a portfolio of premium performing products, all with a longstanding tradition of precision, innovation and quality,” Tom Kapfer, president and CEO of BVI, said in the release. “The addition of Endo Optiks technology to the BVI portfolio furthers our commitment to providing high-quality, innovative solutions that improve safety and provide better outcomes for surgeons and patients.” Read more.

3. Allergan requests preliminary injunction against Valeant, Pershing Square

Allergan has requested that the U.S. District Court for the Central District of California set an expedited schedule for discovery, as well as a motion for a preliminary injunction against Valeant Pharmaceuticals, Pershing Square Capital Management and its principal, William A. Ackman, for federal securities law violations.

As part of the preliminary injunction, Allergan will seek an order prohibiting Valeant, Pershing Square and Ackman from exercising rights and benefits associated with Allergan shares that have been acquired unlawfully, according to a company press release.

The company also announced it will hold a special meeting of stockholders on Dec. 18. The company set Oct. 27 as the record date for stockholders entitled to vote at the special meeting. Read more.

4. Clearside Biomedical secures $16 million in Series B financing

Clearside Biomedical has announced the closure of a $16 million Series B financing.

The clinical-stage biopharmaceutical company reported it plans to use proceeds from the financing to fund the development of its proprietary suprachoroidal space drug administration. Read more.

5. AcuFocus secures $21 million in funding, seeks international growth

AcuFocus announced it has secured $21 million in funding, according to a company press release.

“While we work closely with the [U.S. Food and Drug Administration] on advancing our PMA submission for the Kamra inlay, we are taking steps to expand our sales and marketing organization,” Jim Mazzo, AcuFocus’ executive chairman and CEO, said in the release. “We are also focusing significant R&D resources on development of a new presbyopia-correcting [IOL] that we plan to introduce soon.” Read more.

The competitive landscape for ophthalmic and optometry business revenue has been apparent in recent weeks as industries have announced their Q2 earnings, acquisitions, pending agreements and other breaking news. Here are the Ocular Surgery News editors' top five ophthalmic business news items published at Healio.com:

1. Alcon to acquire WaveTec Vision, full rights to ORA System

Alcon announced it has entered into an agreement to acquire WaveTec Vision, according to a company press release.

Upon completion of the acquisition, Alcon will gain full rights to the ORA System and plans to immediately begin integration of WaveTec into its surgical business franchise, according to the release. Read more.

2. Beaver-Visitec announces acquisition of Endo Optiks

Beaver-Visitec International has acquired Endo Optiks, maker of a novel endoscopy system, according to a company press release.

“For over 80 years, BVI has been known to offer a portfolio of premium performing products, all with a longstanding tradition of precision, innovation and quality,” Tom Kapfer, president and CEO of BVI, said in the release. “The addition of Endo Optiks technology to the BVI portfolio furthers our commitment to providing high-quality, innovative solutions that improve safety and provide better outcomes for surgeons and patients.” Read more.

3. Allergan requests preliminary injunction against Valeant, Pershing Square

Allergan has requested that the U.S. District Court for the Central District of California set an expedited schedule for discovery, as well as a motion for a preliminary injunction against Valeant Pharmaceuticals, Pershing Square Capital Management and its principal, William A. Ackman, for federal securities law violations.

As part of the preliminary injunction, Allergan will seek an order prohibiting Valeant, Pershing Square and Ackman from exercising rights and benefits associated with Allergan shares that have been acquired unlawfully, according to a company press release.

The company also announced it will hold a special meeting of stockholders on Dec. 18. The company set Oct. 27 as the record date for stockholders entitled to vote at the special meeting. Read more.

PAGE BREAK

4. Clearside Biomedical secures $16 million in Series B financing

Clearside Biomedical has announced the closure of a $16 million Series B financing.

The clinical-stage biopharmaceutical company reported it plans to use proceeds from the financing to fund the development of its proprietary suprachoroidal space drug administration. Read more.

5. AcuFocus secures $21 million in funding, seeks international growth

AcuFocus announced it has secured $21 million in funding, according to a company press release.

“While we work closely with the [U.S. Food and Drug Administration] on advancing our PMA submission for the Kamra inlay, we are taking steps to expand our sales and marketing organization,” Jim Mazzo, AcuFocus’ executive chairman and CEO, said in the release. “We are also focusing significant R&D resources on development of a new presbyopia-correcting [IOL] that we plan to introduce soon.” Read more.